DOCSLIB.ORG

Journal 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Journal 2014 Journal of ENT masterclass ISSN 2047-959X Journal of ENT MASTERCLASS® New HARMONIC of Journal FOCUS + Shears ENT MASTERCLASS ® 49% faster than Harmonic Focus® at transecting thin tissue at the tip*. VOL: 7 No: To ind out more please contact your local Ethicon Sales Professional * Versus HARMONIC FOCUS® Shears without Adaptive Tissue Technology, as exhibited in a bench-top study performed with 1 devices on porcine tissue (median transection time of 2.22 sec vs. 4.41 sec for tip cuts on thin tissue, p=0.045) UKESCE14024 ©Johnson & Johnson Medical Limited 2014 Johnson & Johnson Medical Limited Pinewood Campus, Year Book 2014 Nine Mile Ride, Wokingham, Berkshire RG40 3EW UK If you require further information please contact Volume 7 Number 1 [email protected] Please refer always to the Instructions for Use / Package Insert that come with the device for the most current and complete instructions. Also Available: AlsoGaviscon Available: Advance Peppermint GavisconSuspension Advance (sodium Peppermint alginate, potassium Suspensionhydrogen (sodiumcarbonate) alginate, and Gaviscon potassium hydrogenAdvance carbonate) Mint Chewable and GavisconTablets (sodium Advancealginate, Mintpotassium Chewable bicarbonate). Tablets (sodium alginate, potassium bicarbonate). forfor LPR LPR LPRadvice.co.uk LPRadvicSee how it works: LPRade.vice.co.uk/democo.uk See how it works: LPRadvice.co.uk/demo JOINT ESSENTIAL INFORMATION cases of congestive cardiac failure and renal impairment or when taking drugs which can increase JOINTGaviscon ESSENTIAL Advance INFORMATION Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed casesplasma of congestive potassium cardiaclevels. Eachfailure 10 and ml renalcontains impairment 200 mg (2.0or when mmol) taking of calcium drugs whichcarbonate. can increase This GavisconSuspension, Advance Gaviscon Peppermint Advance Flavour Mint Chewable Oral Suspension, Tablets. Gaviscon Advance Aniseed plasmamedicinal potassium product levels. contains Each Methyl 10 ml hydroxybenzoate contains 200 mg and (2.0 Propyl mmol) hydroxybenzoate, of calcium carbonate. which This may cause Suspension,Active substances Gaviscon Gaviscon Advance Advance Mint Chewable Peppermint Tablets. Flavour,Gaviscon Advance Aniseed Suspension: medicinalallergic reactionsproduct contains (possibly Methyl delayed). hydroxybenzoate Gaviscon Advance and Propyl Mint Chewable hydroxybenzoate, Tablets: which Each maytwo-tablet cause ActiveEach 5substances ml dose contains Gaviscon sodium Advance alginate Peppermint 500.0mg Flavour,Gaviscon and potassium hydrogenAdvance Aniseedcarbonate Suspension: 100.0mg allergicdose has reactions a sodium (possibly content delayed). of 103mg Gaviscon (4.5mmol) Advance and a Mint potassium Chewable content Tablets: of 78mg Each (2.0mmol). two-tablet This EachGaviscon 5 ml doseAdvance contains Mint sodiumChewable alginate Tablets: 500.0mg Sodium and alginate potassium 500 mg hydrogen and Potassium carbonate bicarbonate 100.0mg 100 doseshould has bea sodium taken into content account of 103mg when a(4.5mmol) highly restricted and a potassium salt diet is content recommended, of 78mg (2.0mmol).e.g. in some This cases Gavisconmg per tablet.Advance Indications: Mint Chewable Treatment Tablets: of symptomsSodium alginate resulting 500 from mg andthe refluxPotassium of acid, bicarbonate bile and pepsin100 shouldof congestive be taken cardiac into account failure when and renala highly impairment restricted or salt when diet taking is recommended, drugs which e.g.can inincrease some cases plasma mginto per the tablet. oesophagus Indications: such Treatmentas acid regurgitation, of symptoms heartburn, resulting indigestionfrom the reflux (occurring of acid, due bile to and the pepsinreflux of ofpotassium congestive levels. cardiac Each failure two-tablet and renal dose impairment contains 200or when mg (2.0taking mmol) drugs of whichcalcium can carbonate. increase plasma intostomach the oesophagus contents), suchfor instance, as acid regurgitation,after gastric surgery, heartburn, as aindigestion result of hiatus (occurring hernia, due during to the reflux of potassiumGaviscon levels.Advance Each Tablets two-tablet may cause dose containscentral nervous 200 mg system (2.0 mmol) depression of calcium in the carbonate. presence of renal stomachpregnancy, contents), accompanying for instance, reflux after oesophagitis, gastric surgery, including as a symptoms result of hiatus of laryngopharyngeal hernia, during reflux such Gavisconinsufficiency Advance and Tabletsshould maynot be cause used central in patients nervous with system renal failure. depression Due toin itsthe aspartame presence ofcontent renal this pregnancy,as hoarseness accompanying and other voicereflux disorders,oesophagitis, sore including throats and symptoms cough. Canof laryngopharyngeal also be used to treat reflux the such insufficiencyproduct should and notshould be givennot be to used patients in patients with phenylketonuria. with renal failure. Side-Effects: Due to its aspartameVery rarely content (<1/10,000) this assymptoms hoarseness of gastro-oesophagealand other voice disorders, reflux soreduring throats concomitant and cough. treatment Can also with be or used following to treat withdrawal the productpatients should may developnot be given allergic to patients manifestations with phenylketonuria. such as urticaria Side-Effects: or bronchospasm, Very rarely anaphylactic (<1/10,000) or symptomsof acid suppressing of gastro-oesophageal therapy. Dosage reflux Instructions:during concomitant Gaviscon treatment Advance with Peppermint or following Flavour withdrawal Oral patientsanaphylactoid may develop reactions. allergic manifestations such as urticaria or bronchospasm, anaphylactic or ofSuspension, acid suppressing Gaviscon therapy. Advance Dosage Aniseed Instructions: Suspension: Gaviscon Adults andAdvance children Peppermint 12 years Flavourand over: Oral 5-10 anaphylactoidNHS List Price: reactions. Gaviscon Advance Peppermint Flavour Oral Suspension: 250ml - £2.56, 500ml - Suspension,ml after meals Gaviscon and at Advance bedtime Aniseed (one to Suspension: two 5 ml measuring Adults and spoons). children Gaviscon 12 years Advance and over: Mint 5-10 NHS£5.12 List Gaviscon Price: Gaviscon Advance Advance Aniseed PeppermintSuspension: Flavour 250ml Oral- £2.56, Suspension: 500ml - 250ml£5.12 Gaviscon- £2.56, 500mlAdvance - mlChewable after meals Tablets: and atFor bedtime oral administration (one to two after5 ml measuringbeing thoroughly spoons). chewed. Gaviscon Adults Advance and children Mint 12 £5.12Mint GavisconChewable Advance Tablets: Aniseed 60 Tablets Suspension: - £3.07 Marketing250ml - £2.56, Authorisation: 500ml - £5.12 Gaviscon Gaviscon Advance Advance Chewableyears and Tablets: over: One For tooral two administration tablets after aftermeals being and thoroughly at bedtime. chewed. Children Adults under and 12 children years: 12Should MintPeppermint Chewable Flavour Tablets: Oral 60 Suspension- Tablets - £3.07 PL 00063/0612Marketing Authorisation: Gaviscon Advance Gaviscon Aniseed Advance Suspension - PL yearsbe given and over:only on One medical to two advice. tablets Elderly: after meals No dose and modification at bedtime. is Children required under for this 12 age years: group Should Peppermint00063/0108. Flavour Gaviscon Oral Suspension- Advance Mint PL Chewable 00063/0612 Tablets Gaviscon – PL 00063/613 Advance Aniseed Supply Suspension Classification - PL be given only on medical advice. Elderly: No dose modification is required for this age group 00063/0108. Gaviscon Advance Mint Chewable Tablets – PL 00063/613 Supply Classification Contraindications: Hypersensitivity to any of the ingredients, including the esters of Gaviscon Advance Peppermint Flavour Oral Suspension/ Gaviscon Advance Aniseed Suspension - P Contraindications:hydroxybenzoates (parabens).Hypersensitivity Precautions to any of andthe ingredients,Warnings: Care including needs the to estersbe taken of in treating GavisconGaviscon Advance Advance Peppermint Mint Chewable Flavour Tablets Oral Suspension/- GSL Marketimng Gaviscon authorisation Advance Aniseed Holder: Suspension Reckitt - P hydroxybenzoatespatients with hypercalcaemia, (parabens). Precautions nephrocalcinosis and Warnings: and recurrent Care calcium needs tocontaining be taken renalin treating calculi. GavisconBenckiser Advance Healthcare Mint (UK)Chewable Limited, Tablets Dansom - GSL Lane, Marketimng Hull, HU8 7DS.authorisation Holder: Reckitt patientsThere is with a possibility hypercalcaemia, of reduced nephrocalcinosis efficacy in patients and recurrent with very calcium low levels containing of gastric renal acid.Treatment calculi. of BenckiserGaviscon Healthcare and the sword (UK) andLimited, circle Dansom symbol Lane,are trade Hull, marks. HU8 7DS. Therechildren is a youngerpossibility than of reduced12 years efficacy of age is in not patients generally with recommended, very low levels exceptof gastric on medicalacid.Treatment advice.If of Gaviscon and the sword and circle symbol are trade marks. children younger than 12 years of age is not generally recommended, except on medical advice.If Adverse events should be reported. Reporting forms and information can be symptoms do not improve after seven days, the clinical situation should be reviewed. Gaviscon Adverse events should be reported. Reporting forms and information can be symptoms do not improve after seven days, the clinical situation should be reviewed. Gaviscon found at www.yellowcard.gov.uk/yellowcard Adverse events should
Load more

Recommended publications
  • OCSHCN-10G, Medical Eligibility List for Clinical and Case Management Services.Pdf
    OCSHCN-10g (01 2019) (Rev 7-15-2017) Office for Children with Special Health Care Needs Medical Eligibility List for Clinical and Case Management Services BODY SYSTEM ELIGIBLE DISEASES/CONDITIONS ICD-10-CM CODES AFFECTED AUTISM SPECTRUM Autistic disorder, current or active state F84.0 Autistic disorder DISORDER (ASD) F84.3 Other childhood disintegrative disorder Autistic disorder, residual state F84.5 Asperger’s Syndrome F84.8 Other pervasive developmental disorder Other specified pervasive developmental disorders, current or active state Other specified pervasive developmental disorders, residual state Unspecified pervasive development disorder, current or active Unspecified pervasive development disorder, residual state CARDIOVASCULAR Cardiac Dysrhythmias I47.0 Ventricular/Arrhythmia SYSTEM I47.1 Supraventricular/Tachycardia I47.2 Ventricular/Tachycardia I47.9 Paroxysmal/Tachycardia I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillationar I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter I48.4 Atypical atrial flutter I49.0 Ventricular fibrillation and flutter I49.1 Atrial premature depolarization I49.2 Junctional premature depolarization I49.3 Ventricular premature depolarization I49.49 Ectopic beats Extrasystoles Extrasystolic arrhythmias Premature contractions Page 1 of 28 OCSHCN-10g (01 2019) (Rev 7-15-2017) Office for Children with Special Health Care Needs Medical Eligibility List for Clinical and Case Management Services I49.5 Tachycardia-Bradycardia Syndrome CARDIOVASCULAR Chronic pericarditis
    [Show full text]
  • Oral Lesions in Leprosy
    Study Oral lesions in leprosy Ana Paula Fucci da Costa, José Augusto da Costa Nery, Maria Leide Wan-del-Rey de Oliveira, Tullia Cuzzi,* Marcia Ramos-e-Silva Departments of Dermatology & *Pathology, HUCFF-UFRJ and School of Medicine, Federal University of Rio de Janeiro, Brazil. Address for correspondence: Marcia Ramos-e-Silva, Rua Sorocaba 464/205, 22271-110, Rio de Janeiro, Brazil. E-mail: [email protected] ABSTRACT Background: Leprotic oral lesions are more common in the lepromatous form of leprosy, indicate a late manifestation, and have a great epidemiological importance as a source of infection. Methods: Patients with leprosy were examined searching for oral lesions. Biopsies of the left buccal mucosa in all patients, and of oral lesions, were performed and were stained with H&E and Wade. Results: Oral lesions were found in 26 patients, 11 lepromatous leprosy, 14 borderline leprosy, and one tuberculoid leprosy. Clinically 5 patients had enanthem of the anterior pillars, 3 of the uvula and 3 of the palate. Two had palatal infiltration. Viable bacilli were found in two lepromatous patients. Biopsies of the buccal mucosa showed no change or a nonspecific inflammatory infiltrate. Oral clinical alterations were present in 69% of the patients; of these 50% showed histopathological features in an area without any lesion. Discussion: Our clinical and histopathological findings corroborate earlier reports that there is a reduced incidence of oral changes, which is probably due to early treatment. The maintenance of oral infection in this area can also lead to and maintain lepra reactions, while they may also act as possible infection sources.
    [Show full text]
  • Ackerman's Tumour of Buccal Mucosa in a Leprosy Patient
    Lepr Rev (2013) 84, 151–157 CASE REPORT Ackerman’s tumour of buccal mucosa in a leprosy patient MANU DHILLON*, RAVIPRAKASH S. MOHAN**, SRINIVASA M. RAJU***, BHUVANA KRISHNAMOORTHY* & MANISHA LAKHANPAL* *Department of Oral Medicine and Radiology, ITS Centre for Dental Studies and Research, Ghaziabad, India **Department of Oral Medicine and Radiology, Kothiwal Dental College and Research Centre, Moradabad, India ***Department of Oral Medicine and Radiology, Saraswati Dental College, Lucknow, India Accepted for publication 23 April 2013 Summary Leprosy (Hansen’s disease) is a chronic granulomatous disease caused by Mycobacterium leprae (Hansen’s bacillus). Oral manifestations occur in 20–60% of cases, usually in lepromatous leprosy, and are well documented. They may involve both the oral hard and soft tissues. Incidence of verrucous carcinoma/Ackerman’s tumour developing in anogenital region and plantar surfaces of feet in lepromatous leprosy has been sufficiently documented in the literature. However, association of oral verrucous carcinoma with lepromatous leprosy has not been established. We report for the first time a case of verrucous carcinoma of the buccal mucosa occurring in a leprotic patient, with brief review of literature on orofacial manifestations of leprosy. Introduction Leprosy (Hansen’s disease) is a chronic, contagious granulomatous disease caused by Mycobacterium leprae (Hansen’s bacillus). The disease presents polar clinical forms (the ‘multibacillary’ or lepromatous leprosy, and ‘paucibacillary’ or tuberculoid leprosy),
    [Show full text]
  • Level Diagnosis of Cervical Compressive Myelopathy: Signs, Symptoms, and Lesions Levels
    Elmer Press Original Article J Neurol Res • 2013;3(5):135-141 Level Diagnosis of Cervical Compressive Myelopathy: Signs, Symptoms, and Lesions Levels Naoki Kasahata ficult to accurately localize the lesion before radiographic Abstract diagnosis. However, neurological level diagnosis of spinal cord is important for accurate lesion-specific level diagnosis, Background: To elucidate signs and symptoms corresponding to patients’ treatment, avoiding diagnostic error, differential di- each vertebral level for level-specific diagnoses. agnosis, and especially for accurate level diagnosis of other nonsurgical myelopathies. Moreover, level diagnosis should Methods: We studied 106 patients with cervical compressive my- be considered from multiple viewpoints. Therefore, we in- elopathy. Patients who showed a single compressive site on mag- tend to make level diagnosis of myelopathy more accurate. netic resonance imaging (MRI) were selected, and signs, symp- Previously, lesion-specific level diagnoses by determin- toms, and the levels of the MRI lesions were studied. ing a sensory disturbance area or location of numbness in Results: Five of 12 patients (41.7%) with C4-5 intervertebral level the hands had the highest accuracy [1, 2]. Previous stud- lesions showed decreased or absent biceps and brachioradialis re- ies reported that C3-4 intervertebral level lesions showed flexes, while 4 of these patients (33.3%) showed generalized hyper- increased or decreased biceps reflexes, deltoid weakness, reflexia. In comparison, 5 of 24 patients (20.8%) with C5-6 inter- and sensory disturbance of arms or forearms [1, 3, 4], while vertebral level lesions showed decreased or absent triceps reflexes; C4-5 intervertebral level lesions showed decreased biceps however, 9 of these patients (37.5%) showed decreased or absent reflexes, biceps weakness, and sensory disturbance of hands biceps and brachioradialis reflexes.
    [Show full text]
  • Clinical Assessment
    ID Canadian Study of Health and Aging - 3 CLINICAL ASSESSMENT CONSENSUS DIAGNOSTIC OPINION English: 1 To reach 'Part 1 - Final Diagnosis' the following are reviewed: Screening Questionnaire Informant or Caregiver Interview Clinical Assessment, Section 1: Clinician's Evaluation Clinical Assessment, Section 2: Clinician's Preliminary Diagnostic Opinion Neuropsychological Assessment, including Score Sheets and Evaluation Complete 1 Incomplete 2 YES NO Edited 1 2 Editor's # www.csha.ca C-i CONSENSUS DIAGNOSTIC OPINION ID Date of consensus conference / / dd mm yyyy NOTE: Circle only one of the diagnostic categories A to F. Fill in more detail where appropriate. Diagnoses must be made. Confidence in the diagnoses can be recorded for each diagnosis. PART 1 FINAL DIAGNOSIS 1 A. No cognitive impairment B1. Cognitive impairment but no dementia (CIND) (circle one or more of the subcategories below) 1 delirium 6 age-associated memory impairment 15 epilepsy 2 chronic alcohol abuse 7 mental retardation 16 socio-cultural 3 chronic drug intoxication 10 cerebral vascular, stroke 17 social isolation 4 depression 11 general vascular 18 blind/deaf 5 psychiatric disease 12 Parkinson's disease 19 unknown (other than depression) 13 brain tumour 8 other, specify: 14 multiple sclerosis B2. Specify most important of those listed in B.1 C. Alzheimer's Disease (circle only one of 1 or 2): 1 probable 2 possible (circle only one of 2.1 to 2.4): 2.1 atypical presentation/course (e.g. major aphasia, apraxia) specify: 2.2 with vascular components 2.3 with Parkinsonism (EP signs) 2.4 with coexisting disease D. Vascular dementia [ischemic score ] (circle only one of 1 to 4) 1 of acute onset 2 multiple cortical infarct 3 subcortical 4 mixed cortical and subcortical E.
    [Show full text]
  • Level Estimates of Maternal Smoking and Nicotine Replacement Therapy During Pregnancy
    Using primary care data to assess population- level estimates of maternal smoking and nicotine replacement therapy during pregnancy Nafeesa Nooruddin Dhalwani BSc MSc Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2014 ABSTRACT Background: Smoking in pregnancy is the most significant preventable cause of poor health outcomes for women and their babies and, therefore, is a major public health concern. In the UK there is a wide range of interventions and support for pregnant women who want to quit. One of these is nicotine replacement therapy (NRT) which has been widely available for retail purchase and prescribing to pregnant women since 2005. However, measures of NRT prescribing in pregnant women are scarce. These measures are vital to assess its usefulness in smoking cessation during pregnancy at a population level. Furthermore, evidence of NRT safety in pregnancy for the mother and child’s health so far is nebulous, with existing studies being small or using retrospectively reported exposures. Aims and Objectives: The main aim of this work was to assess population- level estimates of maternal smoking and NRT prescribing in pregnancy and the safety of NRT for both the mother and the child in the UK. Currently, the only population-level data on UK maternal smoking are from repeated cross-sectional surveys or routinely collected maternity data during pregnancy or at delivery. These obtain information at one point in time, and there are no population-level data on NRT use available. As a novel approach, therefore, this thesis used the routinely collected primary care data that are currently available for approximately 6% of the UK population and provide longitudinal/prospectively recorded information throughout pregnancy.
    [Show full text]
  • MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002
    MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002 Michigan Department of Community Health Community Public Health Agency and Center for Health Statistics 3423 N. Martin Luther King Jr. Blvd. P. O. Box 30691 Lansing, Michigan 48909 Michigan Department of Community Health James K. Haveman, Jr., Director B-274a (March, 2002) Authority: P.A. 236 of 1988 BIRTH DEFECTS REGISTRY MICHIGAN DEPARTMENT OF COMMUNITY HEALTH BIRTH DEFECTS REGISTRY STAFF The Michigan Birth Defects Registry staff prepared this manual to provide the information needed to submit reports. The manual contains copies of the legislation mandating the Registry, the Rules for reporting birth defects, information about reportable and non reportable birth defects, and methods of reporting. Changes in the manual will be sent to each hospital contact to assist in complete and accurate reporting. We are interested in your comments about the manual and any suggestions about information you would like to receive. The Michigan Birth Defects Registry is located in the Office of the State Registrar and Division of Health Statistics. Registry staff can be reached at the following address: Michigan Birth Defects Registry 3423 N. Martin Luther King Jr. Blvd. P.O. Box 30691 Lansing MI 48909 Telephone number (517) 335-8678 FAX (517) 335-9513 FOR ASSISTANCE WITH SPECIFIC QUESTIONS PLEASE CONTACT Glenn E. Copeland (517) 335-8677 Cytogenetics Laboratory Reporting Instructions I. INTRODUCTION This manual provides detailed instructions on the proper reporting of diagnosed birth defects by cytogenetics laboratories. A report is required from cytogenetics laboratories whenever a reportable condition is diagnosed for patients under the age of two years.
    [Show full text]
  • Diseases of the Digestive System (KOO-K93)
    CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause.
    [Show full text]
  • MW S Rationales Files/Brain Rationale.Pdf
    A RATIONALE FOR THE BRAIN A RATIONALE FOR the BRAIN Assoc. Prof. Warwick Carter MB.BS; FRACGP; FAMA A guide to the diagnosis of diseases that may cause neurological symptoms. 1 A RATIONALE FOR THE BRAIN CONTENTS Introduction SECTION ONE Headache Diagnostic Chart A chart that leads the user through the headache symptoms to possible diagnoses. SECTION TWO Diagnostic Algorithm for Neurological Symptoms Symptoms involving the brain and the conditions that may be responsible SECTION THREE Neurological Conditions The symptoms, signs, investigation and treatment of medical conditions that may cause neurological symptoms. Appendices Mini-Mental Test Glasgow Coma Scale 2 A RATIONALE FOR THE BRAIN INTRODUCTION This book is designed for both the medical student and the doctor who is not a specialist in neurology. It will take the user through a logical rationale in order to diagnose, and then treat, virtually every neurological condition likely to be encountered outside a specialist practice. There are two ways to reach a diagnosis, using the chart in Section One, or the Diagnostic Algorithms in Section Two. In Section One, the chart will guide the user through headcahe symptoms to a selection of possible diagnoses. In Section Two the algorithms will indicate the diagnoses possible with a variety of neurological presenting symptoms. Once a diagnosis has, or number of differential diagnoses have been made, a detailed explanation of the various diagnoses can be found in the largest part of the book, Section Three. This has been written in a style that should be easy to understand by even junior medical students, with technical terms explained in each monograph, but should still be useful to the non-specialist doctor.
    [Show full text]
  • Treatments for Ankyloglossia and Ankyloglossia with Concomitant Lip-Tie Comparative Effectiveness Review Number 149
    Comparative Effectiveness Review Number 149 Treatments for Ankyloglossia and Ankyloglossia With Concomitant Lip-Tie Comparative Effectiveness Review Number 149 Treatments for Ankyloglossia and Ankyloglossia With Concomitant Lip-Tie Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2012-00009-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, TN Investigators: David O. Francis, M.D., M.S. Sivakumar Chinnadurai, M.D., M.P.H. Anna Morad, M.D. Richard A. Epstein, Ph.D., M.P.H. Sahar Kohanim, M.D. Shanthi Krishnaswami, M.B.B.S., M.P.H. Nila A. Sathe, M.A., M.L.I.S. Melissa L. McPheeters, Ph.D., M.P.H. AHRQ Publication No. 15-EHC011-EF May 2015 This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2012-00009-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Original Article Retrospective Analysis of 69 Patients with Melkersson-Rosenthal Syndrome in Mainland China
    Int J Clin Exp Med 2016;9(2):3901-3908 www.ijcem.com /ISSN:1940-5901/IJCEM0016042 Original Article Retrospective analysis of 69 patients with Melkersson-Rosenthal syndrome in mainland China Jian-Jun Tang, Xiang Shen, Jia-Jia Xiao, Xiao-Ping Wang Department of Neurology, Shanghai First Peoples’ Hospital, School of Medicine, Shanghai Jiao-Tong University, Wujing Road 85#, Shanghai 200080, PR China Received September 12, 2015; Accepted December 28, 2015; Epub February 15, 2016; Published February 29, 2016 Abstract: Melkersson-Rosenthal syndrome (MRS) is a rare disease with unclear etiology. The clinical manifestations of MRS are characterized by swelling face and lips, peripheral facial paralysis, and fissured tongue. We summarized 69 patients with Melkersson-Rosenthal syndrome in mainland China by searching for PubMed, and Chinese main electronic databases including Chinese National Knowledge Infrastructure Databases (CNKI) and Wanfang. This disease could occur at any age, including teenagers and aged person. 75.4% of patients with typical MRS triad symptoms, while the others only with one or two initial symptoms. Cheilitis granulomatosa is also a type of MRS. No standard diagnostic criteria has been issued to date, and biopsy is generally needed to make a definite diagnosis. Immunosuppressive therapy is of some efficacy in treating MRS; however, no specific treatment has been identified to treat MRS. Keywords: Melkersson-Rosenthal syndrome, clinical characteristics, treatment Introduction we summarized the MRS case reported in china mainland. Melkersson-Rosenthal syndrome (MRS), also known as recurrent facial palsy syndrome with Method swelling of the face and lips, is a rare neurologi- cal disorder involving skin and mucosal lesions.
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]